Panel Discussion: Neuropsychiatry at a Crossroads: Where Science, Strategy & Deal Making Converge

9:45 am - Wednesday 16th September 2026

  • What indications are you excited about and actively exploring?
  • Which drug modalities are you excited about and actively exploring?
  • In 2026 are we ready for precision psychiatry, and what might we need to improve in terms of diagnostics to get there (genetics, etc.)?

Speakers:

Principal
Vida Ventures
VP, Clinical Development
Lundbeck
Senior Director, External Innovation
Eli Lilly